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A B S T R A C T
Recently, chemotherapy is still widely exploited to treat the residual, infiltrative tumor cells after surgical re-
section. However, many anticancer drugs are limited in clinical application due to their poor water-solubility
(hydrophibic) and stability, low bioavailability, and unfavorable pharmacokinetics. Herein, an amphiphilic
stearic acid-O-carboxymethyl chitosan (SA-CMC) conjugate was synthesized by amide linkage of SA to the
backbone of CMC polymer and then self-assembled into nanoparticles (SA-CMC NPs) with the hydrodynamic
particle size of ~100 nm. Subsequently, Paclitaxel (PTX) as a potent and broad-spectrum anticancer drug was
loaded into SA-CMC NPs by a probe sonication combined with dialysis method. Owing to the multi-hydrophobic
inner cores, the prepared PTX-SA-CMC NPs showed a considerable drug-loading capacity of ~19wt% and a
biphasic release behavior with an accumulative release amount in the range of 70–90% within 72 h. PTX-SA-
CMC NPs remarkably enhanced the accumulation at the tumor sites by passive targeting followed by cellular
endocytosis. Upon the stimuli of acid, PTX-SA-CMC NPs showed exceptional instability by pH change, thereby
triggering the rapid disassembly and accelerated drug release. Consequently, compared with Cremophor EL-
based free PTX treatment, PTX-SA-CMC NPs under pH-stimuli accomplished highly efficient apoptosis in cancer
cells and effectively suppression of tumors by chemotherapy. Overall, PTX-SA-CMC NPs integrating imaging
capacity might be a simple yet feasible PTX nanosystem for tumor-targeted delivery and cancer therapy.
1. Introduction
Cancer is still the leading cause of human death in the world, and
conquering malignant tumors is a major challenge that mankind is fa-
cing [1]. Chemotherapy, one of the most universal methods for cancer
treatments, often results in severely systemic side effects attributing to
unspecific drug delivery to all organs and tissues including healthy ones
[2]. Besides, the majority of anticancer drugs with potential bioactivity
are seriously limited in clinical application due to the poor water-so-
lubility and stability, fast degradation, short blood circulation, severe
multidrug resistance MDR, rapid clearance, non-specific bio-distribu-
tion, low tumor accumulation, and undesired systemic toxicity [2,3].
Fortunately, the rapid developments of nanotechnology in the past few
decades supply an innovative platform for prolonging the lifetime and
life quality of cancer patients due to their significant biodistribution
and bioavailability [4,5]. A rich variety of nano-carriers such as lipo-
somes [6,7], polymeric micelles [8–10], protein based nanoparticles
[11], polymer/drug-drug conjugates [12,13], inorganic nanoparticles
[14,15], dendrimers [16], carbon nanotubes [17], and quantum dots
[18,19] have been successfully developed for delivery hydrophobic
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drug to tumor tissue via passive (enhanced permeability and retention
(EPR) effect mediated passive targeting effect) or active (ligand medi-
ated active targeting effect) targeting [20,21]. Although these nano-
carriers can remarkably enhance the pharmacokinetics and bio-dis-
tribution of anticancer drugs, they are largely limited by poor
biocompatibility and the presence of a number of nonactive excipients
might result in the undesired side effects [17].
Additionally, the polymeric nanoparticles self-assembled by am-
phiphilic conjugates in water solution, as a variety of nanomedicine
delivery systems, have attracted wide attentions over the years [22].
Since the hydrophobic cores of the polymeric nanoparticles are sur-
rounded via the hydrophilic outer shells. Therefore, the inner core can
be regarded as a nano-container to load the hydrophobic anticancer
drugs. Moreover, the circulation lifetime of intravenously injected na-
noparticles can be relatively prolonged owing to the limited uptake via
liver and spleen [22,23]. As the prolonged circulation lifetime of na-
noparticles allows them to accumulate and extravasate at the tumor site
by EPR effect, the reduced uptake by liver and spleen has been used for
the treatment of solid tumors [23]. Overall, nanomedicine delivery
systems based on the polymeric nanoparticles are effective strategy for
passive tumor targeting with long retention time in the bloodstream.
Paclitaxel (PTX) as one of the most effective anticancer drugs has
been widely used in the clinical treatment of various forms of cancer,
including ovarian and breast cancer, nonsmall cell lung carcinoma,
melanoma, head and neck cancer, AIDS-related Kaposi's sarcoma, and
others [24,25]. PTX is an effective promoter of microtubulin poly-
merization which results in cell apoptosis via disturbing the dynamics of
cell divisions. However, the high hydrophobicity of PTX (water solu-
bility 0.3 μg/mL) hampers its clinical applications. To improve its water
solubility, it is usually formulated with Cremophor EL in the clinical
applications. Unfortunately, the application of Cremophor EL is related
in the hypersensitivity reactions, neurotoxicity, and nephrotoxicity in
up to 30% of the patients, and plasticizers can be extracted from in-
travenous infusion lines [26]. To address the problem, the development
of alternative formulations without the application of other harmful
excipients and organic solvents has drawn much attention from re-
searchers.
Among the polysaccharides, chitosan possesses many excellent
properties, such as biocompatibility, biodegradability, bioadhesivity,
and non-toxicity that make it suitable as a nano biomedical material.
Nonetheless, chitosan without amphiphilicity could not form nanomi-
celle. In the past decades, chitosan-based micellar system has been
developed via grafting hydrophobic groups to the chitosan backbone
and then used as the delivery carriers for genes [27], peptides [28], and
antitumor drugs [29]. The chitosan-based amphiphilicity can form
micelles by self-assembly in water solution.
In our previous study, SA as an endogenous long-chain saturated
fatty acid has excellent biocompatibility and low toxicity, and is
available for pharmaceutical use. The CMC hydropholic polymer was
conjugated with SA successively via chemical coupling. Subsequently,
PTX as a model anticancer drug was successfully encapsulated within
SA-CMC NPs. These newly developed nanomedicine delivery systems
could be expected to enhance the targeting and therapeutic effect
greatly (Scheme 1c). The physicochemical characterization, in vitro
drug release, in vitro cytotoxicity, in vitro cellular uptake, in vivo passive
targeting effect and biodistribution, and in vivo antitumor efficiency of
the advanced PTX-SA-CMC NPs were researched in detail.
2. Materials and methods
Paclitaxel (PTX, purity grade > 99%) was purchased from Tianfeng
Biological engineering Co., Ltd., Shenyang, China. O-carboxymethyl
chitosan (CMC, MW=3.5× 105, degree of deacetylatio n=85.2%)
was provided by Honghai biochemistry Co., Ltd., Qingdao, China.
Stearic acid (SA) was purchased from Chemical Reagent Co., Ltd.,
Shanghai, China. The near-infrared (NIR) dye, Cy5.5 was purchased
from PE Company, USA. Hoechst 33258 were provided by Invitrogen
(USA). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-hy-
droxysuccinimide (NHS), 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphe-
nyltetrazolium bromide (MTT), and 2, 4, 6-trinitrobenzene sulfonic acid
(TNBS) were obtained from Sigma Chemical Co., Ltd., St. Louis, USA.
BEL-7402 human liver cancer cell lines were obtained from Cancer
Research Center, Medical College, Xiamen University. Dulbecco's
minimum essential medium (DMEM) was obtained from GE Healthcare
Life Sciences HyClone Laboratories. RPMI-1640, penicillin-strepto-
mycin, and tryposin were obtained from Gibco BRL, USA. Pyrene was
purchased from Aldrich Chemical Co., Ltd., USA, was purified by
double recrystallization from absolute ethanol. Sodium salicylate was
supplied by Wulian Chemical plant, China. Fetal bovine serum (FBS)
was supplied by Sijiqing Biologic, China. The dialysis bags
(MWCO=3500 and 7000 DA) were from Spectrum Laboratories, USA.
All other chemicals and reagents were analytical or chromatographic
grade unless otherwise noted. All experiments were performed in
compliance with the relevant laws and institutional guidelines. The
experiments were carried out in accordance with the guidelines issued
by the Ethical Committee of Xiamen University.
2.1. Synthesis of SA-CMC conjugate
The amphiphilic SA-CMC conjugate was synthesized via chemical
conjugation of CMC with SA in the presence of EDC. Briefly, in a typical
reaction, CMC (1.0 g) was dissolved in 30mL of ultrapure water. SA
(0.4 g) and EDC (0.81 g) were dissolved in 20mL of ethanol by soni-
cation treatment (JY92-II, Kunshan Ultrasonic Instrument Co. Ltd.,
Jiangshu, China) in the water bath. Subsequently, CMC solution was
added to the mixture under magnetic stirring at 400 rpm. The reaction
mixture was carried on stirring at 80 °C for 6 h and then cooled to room
temperature. The reaction mixture was stirred sequentially for an ad-
ditional 24 h. The prepared product was dialyzed against ultrapure
water using dialysis membrane (MWCO 7 kDa) for 48 h to completely
remove other water-soluble byproducts and then dried in a vacuum
oven. The dried product was dispersed in 20mL of ethanol and then
treated with sonication to completely remove the un-reacted SA. The
sonication step was repeated two times. The obtained suspension was
filtered to collect the precipitate through 0.45 μm millipore filter. The
precipitate was then dried, and the final product of SA-CMC conjugate
was received.
2.2. Characterizations of SA-CMC conjugate
The Fourier transform infrared spectroscopy (FT-IR) spectra of CMC
and SA-CMC conjugate powder were analyzed using Nicolet Avatar 380
Fourie Transfer Infrared Spectrometer
Next, 1H nuclear magnetic resonance (NMR) spectra of CMC and SA-
CMC conjugate were analyzed on a NMR Spectrometer (400 Hz, Bruker,
Switzerland). CMC and SA-CMC conjugate was dissolved in D2O solu-
tion.
2.3. Determination of the degrees of substitution (DS)
DS, referred to the SA per 100 sugar residues of CMC, was measured
via TNBS method. Briefly, 20mg of SA-CMC conjugate was dissolved in
20mL of ultrapure water. Subsequently, 4 mL of SA-CMC conjugate
solution was added to 4mL of 4% NaHCO3 and 4mL of 0.1% TNBS at
40 °C for 1.5 h. 2mL of HCl (2 N) was supplemented sequentially. The
UV absorbance at 344 nm of the product against a blank was prepared
with sodium hydrogen carbonate solution, TNBS solution, and ultra-
pure water under the same process, and determined via UV spectro-
photometer (HELIOS ALPHA, Varian Instrument, USA). The amount of
SA substitution was calculated by a calibration curve acquired via the
amino-group measurement of a series of solutions with increasing the
amount of CMC.
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2.4. Determination of critical aggregation concentration (CAC)
To measure the self-aggregation behavior of SA-CMC conjugate and
its CAC value, the pyrene as a fluorescence probe was used in our
previous study. In brief, 6 mg of pyrene was dissolved in 50mL of
acetone to prepare the pyrene stock solution. Subsequently, the pre-
pared pyrene stock solution was diluted with acetone for an additional
100 times. Exact 0.5 mL aliquots of pyrene solution at a concentration
of 0.0012mg/mL were precisely transferred into test tubes and then the
solvent was evaporated in dark at 50 °C. 5mL of SA-CMC conjugate
solution at concentrations ranging from 1.0mg/mL to 10−4 mg/mL was
added to test tubes. The final concentration of pyrene in mixtures was
controlled at 10−7 M. The emission spectra of mixture were determined
by using fluorometer (LS-55, PE Co., Ltd., USA) (excitation wavelength
of 335 nm).
2.5. Preparation of SA-CMC NPs and PTX-SA-CMC NPs
The amphiphilic SA-CMC conjugate was firstly self-assembled into
SA-CMC NPs by probe sonication method in aqueous solution. In brief,
SA-CMC conjugate was dispersed in ultrapure water under gentle
shaking at 25 °C for 12 h, followed by sonication exploiting a probe type
sonifier (Kunshan Ultrasonic Instrument Co. Ltd., Jiangshu, China) at
60W for 2min in an ice bath. The sonication step was repeated five
times. The sample solution was filtered through 0.45 μm millipore filter
to completely remove dust.
Next, the probe sonication-dialysis method was used to prepare
PTX-SA-CMC NPs. Briefly, predetermined PTX (0.6–1.8mg) were dis-
solved in methanol, and then the self-assembled SA-CMC NPs disper-
sion were slowly added under stirring followed by sonication using a
probe type sonifier in an ice bath. Subsequently, to obtain the PTX-
loaded self-assembled SA-CMC NPs, the residual methanol solvent was
removed by dialysis (Millipore dialysis tube, MWCO, 14 kDa, USA). The
impurity and dust in the PTX-loaded self-assembled SA-CMC NPs so-
lution were removed by passing through 0.45 μm millipore filter, fol-
lowed by lyophilization.
2.6. Characterizations of SA-CMC NPs and PTX-SA-CMC NPs
The samples for the transmission electron microscope (TEM,
JEM2100, Japan) observation were prepared by dropping a solution of
SA-CMC NPs and PTX-SA-CMC NPs onto a 300-mesh copper grid coated
with carbon. The sample grid was allowed to dry completely at 25 °C.
Observation was performed at 80 kV.
Next, the hydrodynamic diameter and zeta potential of SA-CMC NPs
and PTX-SA-CMC NPs were determined via dynamic light scattering
(DLS) and electrophoretic light scatterin (ELS) using a Malvern
Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, U.K.).
Scheme 1. (a) Synthetic route of SA-CMC. The SA-CMC conjugate was synthesized via the chemical coupling between carboxyl group of SA molecule and the amino
group of CMC molecule, subsequently (b) Illustration of the self-assembly of PTX-SA-CMC NPs. (c) Schematic of drug delivery of PTX-SA-CMC NPs. Through the EPR
effect-mediated passive targeting and the cellular endocytosis, PTX-SA-CMC NPs realized preferential tumor accumulation, pH-responsive drug release, and highly
effectively chemotherapy after intravenous injection.
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2.7. Drug-loading capacity and encapsulation efficiency
In this experiment, to measure the concentration of PTX in PTX-SA-
CMC NPs, high performance liquid chromatography (HPLC, Agilent
Technologies G171BA 1200 series, German) were used according to the
following conditions: stationary phase, Diamohsil TM C18 column
(250mm×4.6mm, 5 μm); temperature, 25 °C; mobile phase, me-
thanol: water (75:25, v/v), freshly prepared, filtered through a 0.22mm
Millipore membrane filter before using, and degassed by a sonication
method; elution flow rate, 1 mL/min; detection wavelength, 227 nm. A
calibration curve was used for quantification via calculating the PTX
concentration of a dilution series of free PTX in PBS. Encapsulation
efficiency and drug-loading content of PTX were calculated using the
following formula [30]:
=PTX encapsulation efficiency (%)
Weight of Encapsulation
Initial Weight
PTX
Dox
=PTX loading efficiency (%)
Weight of Encapsulation
Initial Weight
PTX
Tatal
2.8. In vitro drug release of PTX-SA-CMC NPs
The in vitro release behavior of PTX from PTX-SA-CMC NPs was
measured by dialysis technique using the cellulose ester membrane
tube. A certain amount of PTX-SA-CMC NPs into a dialysis tube (MWCO
7 kDa) was immersed into 57mL of phosphate-buffered saline (PBS)
containing 0.1M of sodium salicylate. The system was gently shaken
under controlled condition at 37 °C in a water bath at 100 rpm. At a
predesigned time point, 3 mL of the release medium was completely
withdrawn and then replaced with the 3mL of fresh PBS containing
0.1 M of sodium salicylate. The release amount of PTX was measured by
UV–vis absorption spectroscopy. The cumulative release amount was
calculated using the following formula.
=
× ∑ + ×
×=
−
Cumulative release(%)
1 Ci 60 Cn
weight of drug in nanosystems
100%i 1
n 1
(2)
where Ci means the concentration of CUR drug in dialysate at i time.
2.9. Cell culture
BEL-7402 (human liver cancer) cell lines were cultured in RPMI-
1640. BEL-7402 cell lines were obtained from Cancer Research Center,
Medical College, Xiamen University and grew at the culture media
supplemented with 10% FBS and 1% penicillin-streptomycin (100 U/
mL). The cells were cultured in an incubator (Thermo Scientific) at
37 °C in a humidified atmosphere of 5% CO2.
2.10. In vitro cytotoxicity of PTX-SA-CMC NPs
In vitro cytotoxicity was evaluated via MTT assay according to the
manufacturer's suggested procedure. BEL-7402 cells were exposed to
PTX-SA-CMC NPs with different PTX concentrations (0.01, 0.1, 1, and
10 μg/mL) for 48 h. The data was expressed by the percentage of the
relative cell viability. Cremophor EL, Cremophor EL-based PTX and SA-
CMC NPs were used as controls.
2.11. In vitro cellular uptake of PTX-SA-CMC NPs
To realize fluorescence labeling, Cy5.5-labeled PTX-SA-CMC NPs
(Cy5.5-PTX-SA-CMC NPs) (14.9 wt%) were prepared as follows: 1 mg of
Cy5.5-NHS was dissolved in 25mL of anhydrous DMSO and then
dropped into the SA-CMC conjugate solution (110mg/40mL) in
anhydrous DMSO. The reaction mixture was stirred overnight at 25 °C
and dialyzed against ultrapure water using a cellulose membrane
(MWCO 7 kDa) for 2 d. The blue solution was lyophilized and blue
powder (Cy5.5-PTX-SA-CMC NPs) was obtained. Lastly, Cy5.5-PTX-SA-
CMC NPs were prepared by a probe sonication combined with dialysis
method described as above.
Next, to visually trace the cellular uptake of PTX-SA-CMC NPs, the
in vitro cellular uptake of Cy5.5-PTX-SA-CMC NPs was carried out by
confocal laser scanning microscopy (CLSM). BEL-7402 cells were
seeded into 6-well plates at a density of 1.0× 104 cells per well, in-
cubated at 37 °C for 24 h, and then treated with Cy5.5-PTX-SA-CMC NPs
at regular time points (at 1, 3, 6, and 24 h) at 37 °C. After treatment, the
cells were washed three times and then fixed by 4% paraformaldehyde
for 3min at 25 °C. Subsequently, the cells were washed with PBS and
the nuclei were stained by Hoechst 33258 for 10min. Finally, the cells
were imaged using a Olympus FV1000 CLSM with excitation at 360 nm
for Hoechst 33258 and 640 nm for Cy5.5.
2.12. In vivo biodistribution of PTX-SA-CMC NPs
All female athymic nude mice (6 weeks, female, 16–18 g) were
provided by Shanghai SLAC Laboratory Animal CO, LTD. We sub-
cutaneously injected BEL-7402 cells into the dorsal side of mice to es-
tablish BEL-7402 tumor-bearing models. Cy5.5-PTX-SA-CMC NPs were
prepared by the method described as above for in vivo fluorescence
imaging. When the tumor diameter was ~8mm, physiological saline
(100 μL) and Cy5.5-PTX-SA-CMC NPs (5mg/kg in 100 μL of physiolo-
gical saline) were intravenously injected via the tail vein into BEL-7402
tumor-bearing mice. The in vivo passive tumor targeting and imaging
was observed at a predetermined point after injection using a
MaestroTM in vivo imaging system (Cambridge Research and
Instrumentation, Woburn, MA, USA).
Next, to provide a substantial evidence of the tumor specificity of
PTX-SA-CMC NPs, ex vivo fluorescence imaging was further performed
in BEL-7402 tumor-bearing mice. At 72 h post-injection, the Cy5.5-PTX-
SA-CMC NPs-treated mice were sacrificed, and the tumor and major
organs (tumor, liver, spleen, lung, kidney, and heart) were excised,
followed by washing the surface with 0.9% NaCl. The resulting data
were used to identify, separate, and remove the contribution of auto-
fluorescence in analyzed images. All data were calculated by the region-
of-interest (ROS) function of Analysis Workstation software (ART
Advanced Research Technologies Inc., Montreal, Canada).
2.13. In vivo antitumor efficiency of PTX-SA-CMC NPs
The antitumor efficiency of PTX-SA-CMC NPs was evaluated in BEL-
7402 liver tumor-bearing Kunming mice. We subcutaneously injected
BEL-7402 liver cancer cells into the dorsal side of mice to establish BEL-
7402 liver tumor-bearing models. When the tumor diameter was
~8mm, these tumor-bearing mice (10 per group) were intravenously
injected via the tail vein with Cremophor EL-based PTX, PTX-SA-CMC
NPs (14.9 wt%), SA-CMC NPs alone, and physiological saline.
Cremophor EL-based PTX and PTX-SA-CMC NPs were given at 0, 4, and
8 day so that the PTX dose would be 20mg/kg (was the maximum
tolerated dose). The tumor size was calculated by a×b2/2, where a
represented the largest diameter and b represented the smallest dia-
meter. The survivals of mice were also recorded.
3. Results and discussion
3.1. Synthesis and characterization of SA-CMC conjugate
CMC, a hydrophilic chitosan derivative, has two kinds of active
groups, which can be functionalized by chemical coupling. One kind of
them is hydroxyl group from C6-OH and C3-OH, the other kind is amino
group. Generally, to endow CMC with some potential characteristics,
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peptide and alkyl are grafted to its molecule via coupling reaction. SA as
an endogenous long-chain saturated fatty acid has excellent bio-
compatibility and low toxicity, and is available for pharmaceutical use.
Therefore, the amphiphilic SA-CMC conjugate was first synthesized via
an amine-reactive coupling reaction between the amino group of CMC
molecular and the carboxyl group of SA molecular (Scheme 1a). In
brief, EDC, a coupling cosslinker could be react with the carboxyl group
of SA molecular and give an active intermediate-O-acylisourea deriva-
tion. Further addition of CMC including primary amino groups pro-
duced hydrophobically modified CMC amphiphiles via a stable amide.
The resultant mixture was dialyzed against ultrapure water to remove
by-product (isourea) and the remained EDC, and the excess of SA was
washed by ethanol. Finally, the lyophilized SA-CMC conjugate could be
easily dispersed in ultrapure water.
The chemical structure of CMC and SA-CMC was measured by FTIR
and 1H NMR analysis. As shown in Fig. 1a, the characteristic absorption
peaks of CMC at 3419 cm−1, 2929 cm−1, 1601 cm−1, 1411 cm−1,
1325 cm−1, and 1065 cm−1 could be ascribed to stretching vibration of
the hydroxyl group, CeH stretching vibration, amide NeH bending,
stretching vibration of hydroxyl group in the carboxyl group, the amide
III stretching (CeN stretching vibration), and CeO stretching vibration,
respectively. Moreover, our results were well consistent with some lit-
eratures [31,32]. In comparison with CMC, the characteristic absorp-
tion peaks of SA-CMC conjugate at 1697 cm−1and 1655 cm-1 were re-
levant to the presence of the amide I stretching (C]O bending of the
secondary amide) and the amide II stretching (NeH bending of the
secondary amide), respectively. Besides, the characteristic absorption
peaks at 2919 and 2850 cm−1 could be attributed to the asymmetric
and symmetric CeH stretching modes of –CH2 groups of SA, respec-
tively. These results demonstrated that an amide linkage was formed
between amino groups of CMC molecular and carboxyl groups of SA
molecular.
Next, to further demonstrate the successful synthesis of SA-CMC
conjugate, the 1H NMR spectra of CMC and SA-CMC congjugate were
shown in Fig. 1b. These proton signals of CMC at 2.10, 2.74, 3.77, 4.51,
and 4.87 ppm could be attributed to CH3 (acetamido group of chitosan),
CH2 (carboxymethyl group), CH (carbon 2 of glucosamine ring with the
substituted amino group), CH (carbon 3, 4, 5 and 6 of glucosamine
ring), and CH (carbon 1 of glucosamine ring). In comparison with CMC,
the new proton signals of SA-CMC conjugate at 0.49, 0.98, and
1.19 ppm could be observed. The result indicated that SA was suc-
cessfully linked to CMC.
Next, we measured the degree of DS via the TNBS method. DS, re-
ferred to the SA per 100 sugar residues of CMC, increased with in-
creasing the feeding mole ratio of SA. A series of SA-CMC conjugates
with different DS could be synthesized via controlling the feed ratio of
SA and EDC to CMC. TNBS could react with the remained primary
amino residues in SA-CMC conjugate. The DS of the SA-CMC conjugate
was determined as ~13.8%.
3.2. Determination of critical aggregation concentration (CAC)
To measure the self-aggregation behavior of SA-CMC conjugate and
its CAC value, the pyrene as a fluorescence probe was widely used [33].
Fig. 1c showed the fluorescence emission spectra of pyrene at different
concentrations of SA-CMC in ultrapure water after sonication. The total
fluorescence intensity of pyrene significantly increased with increasing
the concentration of SA-CMC conjugate. The result implied that SA-
CMC conjugate was aggregated to form hydrophibic micro-domains and
the pyrene molecular was transferred from aqueous media into these
micro-domains. Additionally, in the pyrene emission spectra, there
were five vibrational peaks. The intensity ratio of the first peak at
372 nm and the third peak at 385 nm (I372/I385) was extremely sensitive
to micro-environment. This could be attributed to the fact that
Fig. 1. (a) FTIR and (b) 1H NMR spectra of CMC and SA-CMC conjugate. (c) The fluorescence emission spectra of pyrene (6.0× 10−7 M) dissolved in an aqueous
solution at 25 °C were affected by the different concentrations of SA-CMC co. (I) 1, (II) 0.1, (III) 0.05, (IV) 0.01, (V) 0.005, (VI) 0.001, (VII) 0.0005, and (VII)
0.0001mg/mL. The spectra were accumulated with an integration time of 5 s/1 nm (excitation wavelength of 335 nm). (d) Intensity ratio (I372/I385) for pyrene in PBS
(pH 7.2) and a function of the concentrations of SA-CMC.
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increasing the polarity of the medium induced an increase in the in-
tensity of the first peak I372, corresponding to the forbidden transition.
On the contrary, the third the intensity of the third peak I385, corre-
sponding to the allowed transition, was not changed. Besides, the value
of the intensity ratio was higher in the majority of polar media. [34]
Thus the CAC value was the threshold concentration of self-aggregate
formation via intramolecular or intermolecular association. Usually, the
CAC value could be measured from the alteration of the I372/I385value
of pyrene in the existence of polymeric amphiphiles.
Next, we studied the alterations of the I372/I385 values as a function
of the concentrations of SA-CMC conjugate. The I372/I385 values were
close to 1.87 of pyrene in PBS solution (pH 7.2) at low concentrations.
Subseqently, with further increasing concentration, The I372/I385 values
showed a linear decrease (Fig. 1d). Thus the CAC value was tested as
0.0117mg/mL via the intercept of two straight lines, which was much
lower compared with that of the traditional surfactants such as sodium
dodecyl sulfate in ultrapure water (2.3 mg/mL). [35] The stable SA-
CMC NPs with lower CAC value could preserve their own structural
stability in physiological condition during the circulation. However, in
our previous study we found it was relatively difficult for CMC mole-
cules to aggregate in the range of concentrations [36]. Therefore, It
could be speculated that the aggregation degree of SA-CMC conjugate
in water was attributed to the hydrophobic interactions of SA portions.
3.3. Preparation and characterizations of PTX-SA-CMC NPs
The amphiphilic SA-CMC conjugate was firstly self-assembled into
SA-CMC NPs in aqueous environment. Subsequently, PTX as a hydro-
phobic anticancer drug molecular was physically encapsulated inside
the SA-CMC NPs to form PTX-SA-CMC NPs. The morphology of the SA-
CMC NPs and PTX-SA-CMC NPs was observed by TEM (Fig. 2a and b).
TEM images clearly showed that the SA-CMC NPs and PTX-SA-CMC NPs
were spherical shape, excellent aqueous dispersibility, and uniform
diameter distribution. The mean diameter of PTX-SA-CMC NPs was
slightly larger compared with that of SA-CMC NPs. Significant core-
shell structure could be observed in PTX-SA-CMC NPs (Fig. 2c). More
interestingly, PTX-SA-CMC NPs exhibited multi-core spherical char-
acteristic when the TEM image was magnified from 5000 to 8000-fold
(Fig. 2d). It could be deduced that the self-assembled SA-CMC NPs
accord with multi-core model which was first brought forward by
Akiyoshi et al. in 1997 [37]. The mechanism of formation of self-as-
sembled SA-CMC NPs and PTX-SA-CMC NPs was shown in Scheme 1b,
SA-CMC conjugate was composed by the hydrophilic carboxymethy of
CMC and the hydrophobic portions of SA. In the aqueous phase, the
amphiphilic SA-CMC conjugate was self-assembled into NPs, the hy-
drophobic cores of polymeric NPs were encircled with hydrophilic
outer shells. Therefore, the inner core could be acted as a nano-con-
tainer for accommodating the hydrophobic anticancer drugs, and PTX
was entrapped into the inner cores by hydrophobic interactions be-
tween drug and core domain.
The amphiphilic SA-CMC conjugate formed SA-CMC NPs
spontaneously in water solution (PBS or ultrapure water). Dynamic
light scattering (DLS) demonstrated that SA-CMC NPs were of the mean
hydrodynamic diameter of 138.2 nm, the polydispersity index (PDI) of
0.134, and the zeta potential of about−17.2mV (Table 1). The average
diameter of these NPs measured by TEM was ~98 nm which was
smaller compared with the mean hydrodynamic diameter determined
by DLS. This was mainly attributed to the process involved in pre-
paration of samples. Therefore, due to solvent effect, the diameter
measured by DLS was larger compared with that determined by TEM. In
addition, the mean diameter of PTX-SA-CMC NPs was slightly larger
than the SA-CMC NPs due to the entrapment of PTX drug into the inner
cores, and the average diameter measured by TEM increased from 106
to 123 nm along with the increase of PTX drug-loading capacity.
Therefore, we forecasted that the small size (about 100 nm), negative
charge, favorable stability in biological condition may be suitable for
the EPR effect at the site of a solid tumor [23,38]. Moreover, the size of
PTX-SA-CMC NPs could not only make them ideal drug delivery system
for delaying macrophage clearance in reticular endothelial system
(RES), but also enhance their vascular permeability. These results in-
dicated that PTX-SA-CMC NPs could exhibit a passive tumor targeting
with long retention time in the bloodstream.
3.4. Drug-loading capacity and encapsulation efficiency
Drug-loading capacity, encapsulation efficiency, and their re-
spective average diameter of PTX-SA-CMC NPs were listed in Table 1.
With the feed-weight ratio of PTX adding from 10% to 30%, the PTX
drug-loading capacity increased from 8.6% to 18.8%. Meanwhile, the
PTX encapsulation efficiency reduced from 86.0% to 62.0%. Based on
the diameter and the drug-loading characteristic, the optimal feed-
weight (20%) ratio was chosen to prepare PTX-loaded SA-CMC NPs.
The solubility of PTX in micellar systems self-assembled by the SA-CMC
conjugatewas up to 1.86mg/mL that was about 2000-fold higher
compared with that of the saturated concentration of PTX in ultrapure
water. The PTX-loading capacity was obviously greater compared with
the other polysaccharide-based amphiphiles and SA-CMC NPs. [39,40]
This higher drug-loading capacity of PTX-SA-CMC NPs was likely at-
tributed to the presence of multi-hydrophobic inner cores.
3.5. In vitro drug release of PTX-SA-CMC NPs
Dialysis method was used to research the release profile of PTX from
PTX-SA-CMC NPs. For in vitro release profiles of water-insoluble drugs
like PTX, the choice of the medium is vital because such drugs are not
easily released in the absence of detergents or organic solvents.
Nevertheless, the traditional detergents or organic solvents frequently
disintegrate the self-assembled NPs, which may have an influence on
the release profile of PTX. In our previous work, to induce the release of
PTX from the PTX-CA-CMC NPs, sodium salicylate was successfully
exploited as the hydrophobic agent. [40] Thus, the in vitro release be-
havior of the self-assembled PTX-SA-CMC NPs was administered in PBS
Fig. 2. TEM image of SA-CMC NPs (a, ×5000) and PTX-SA-CMC NPs (14.9%) (b, c, ×5000; d, ×8000) in ultrapure water (1 mg/mL).
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with 0.1 M sodium salicylate at 37 °C.
To measure the release profile of PTX from PTX-SA-CMC NPs with
different PTX-loading content (8.60, 14.90, and 18.80 wt%, respec-
tively), these PTX-SA-CMC NPs were dispersed in PBS with 0.1 M so-
dium salicylate, and then dialyzed at 37 °C for 140 h. As shown in
Fig. 3a, the release of PTX from PTX-SA-CMC NPs (14.9 wt%) shown a
biphasic stage. The initial stage was a burst release stage, which could
be convenient for the inhibition of the tumor cell growth in a short
time. And the subsequent stage was a sustained release stage, which
could offer the probability of continually fighting against the tumor
cell. Besides, the initial burst effect was observed within 12 h, in which
nearly 40% of PTX was released from SA-CMC NPs. Subsequently, PTX
was released in a continuous and sustained way for up to 140 h,
reaching the cumulative release rate close to 96%. Therefore, the self-
assembled SA-CMC NPs delayed the release process of PTX. The similar
release characteristic was also observed in PTX-SA-CMC NPs with dif-
ferent loading capacity (8.60 and 18.80 wt%). However, the release rate
decreased with the increase of PTX-loading capacity, probably due to
the drug crystal formed in the inner cores when the drug concentration
was relatively high.
In addition, to determine the release profile of PTX from PTX-SA-
CMC NPs, they were dispersed in PBS comprising 0.1 M sodium sali-
cylate with pH 7.4, 6.8, and 5.5, respectively, and then dialyzed at 37 °C
for 140 h. AS exhibited in Fig. 3b, PTX-SA-CMC NPs showed sig-
nificantly pH-dependent release behavior. Moreover, It could be found
that PTX release from PTX-SA-CMC NPs was lower at pH 7.4 (about
Table 1
Characteristics of SA-CMC NPs and PTX-SA-CMC NPs.
Sample Feed ratio of PTX/SA-
CMC (%)
Loading capacity of PTXa
(wt%)
Encapsulation efficiency of PTXb
(%)
Mean diameters (nm) PDI Zeta potential
(mV)
SA-CMC NPs – – – 98 ± 11c
138.2 ± 21.3d
0.134 ± 0.012 −17.2
PTX-SA-CMC NPs (10 wt
%)
10 8.6 ± 0.3 86.0 ± 4.3 106 ± 19c
145.8 ± 23.1d
0.225 ± 0.012 −23.2
PTX-SA-CMC NPs (20 wt
%)
20 14.9 ± 0.5 74.5 ± 3.8 115 ± 13c
151.5 ± 29.6d
0.232 ± 0.015 −25.6
PTX-SA-CMC NPs (30 wt
%)
30 18.8 ± 0.9 62.0 ± 2.9 123 ± 24c
157.6 ± 22.4d
0.185 ± 0.012 −27.8
a Loading capacity of PTX in SA-CMC NPs were measured via encapsulation.
b Encapsulation efficiency of PTX in SA-CMC NPs was calculated from the ratio of loading amount of PTX to feed amount of PTX in SA-CMC NPs.
c Average diameter of each n was measured using TEM.
d Average diameter of each particle (1 mg/mL in PBS) was measured via DLS.
Fig. 3. (a) PTX release profiles from PTX-SA-CMC NPs with different drug-loading capacity at 37 °C in PBS with 0.1M sodium salicylate. (b) PTX release profiles from
PTX-SA-CMC NPs with drug-loading capacity of 14.9% at 37 °C in PBS comprising 0.1M sodium salicylate with different pH value. Data represents mean ± s. d.
(n=3). (c) In vitro cytotoxicity of SA-CMC NPs and PTX-SA-CMC NPs (14.9 wt%) measured using MTT assay. Data represents mean ± s. d. (n= 5). (d) In vitro
cellular uptake and intracellular drug delivery of Cy5.5-PTX-SA-CMC NPs (14.9 wt%). CLSM images of BEL-7402 cells incubated with Cy5.5-PTX-SA-CMC NPs
(14.9 wt%) for 1, 3, 6, and 24 h incubation (original magnification, × 400). The cell nuclei were stained with Hoechst 33258. False-color Blue: Hoechst 33258. False-
color red: Cy5.5. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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65%) than at pH 5.0 (nearly 85%) at 48 h. This pH-dependent PTX re-
lease could be ascribed to the increased PTX solubility and weakened
interactions between the PTX and SA-CMC conjugate under acidic
conditions. This release manner might be advantageous to controlled
and sustained drug release. The results indicated PTX-SA-CMC NPs
could maintain a relatively slower release rate in the blood circulation
with neutral pH, and turn to a relatively faster release rate in the mildly
acidic tumor tissue and significantly acidic endo/lysosomes inside
tumor cells. Notably, the accumulative release rate was in range of
73–90% within 72 h. the result implied that PTX-SA-CMC NPs could
maintain drug release in a long period. It might be a great improvement
to SA-grafted chitosan oligosaccharide self-assembled micelles.
3.6. In vitro cytotoxicity of PTX-SA-CMC NPs (14.9 wt%)
To explain the cell-killing effect of PTX-SA-CMC NPs, BEL-7402
human liver cancer cells were treated with the Cremophor EL,
Cremophor EL-based PTX, SA-CMC NPs, and PTX-SA-CMC NPs. The cell
viability was evaluated using MTT assay. As shown in Fig. 3c, PTX-SA-
CMC NPs exhibited obviously concentration-dependent cytotoxicity.
Moreover, PTX-SA-CMC NPs exerted some extent of cancer cell-killing
effect, BEL-7402 cells treated with PTX-SA-CMC NPs retained higher
viabilities than those exposed to Cremophor EL-based PTX. The result
could be ascribed to the fact that Cremophor EL enhanced the cyto-
toxicity of free PTX. It was also explained that the cytotoxic PTX mo-
lecules were released from PTX-SA-CMC NPs in a sustained and pro-
longed manner, resulting in a reduced cytotoxicity compared with free
PTX in a relatively short time. Besides, when BEL-7402 cells were
treated with SA-CMC NPs at various concentrations used in this study,
the majority of cells were viable and cell viability remained above 96%.
The result implied that the empty SA-CMC NPs (was exactly safe and
biodegradable) had little cytotoxicity against BEL-7402 cells. As a main
composition of fat, SA was biocompatible with low toxicity. It was also
reported that CMC showed excellent biocompatibility. [36,41] In a
word, the cytotoxicity of PTX-SA-CMC NPs was resulted in the released
PTX but not was induced by SA-CMC NPs. Therefore, PTX-SA-CMC NPs
might have potential as an effective and safe drug carrier for cancer
therapy.
3.7. In vitro cellular uptake of PTX-SA-CMC NPs (14.9 wt%)
To track the cellular uptake of PTX-SA-CMC NPs, Cy5.5 as a
Fig. 4. (a) In vivo NIR fluorescence images of BEL-7402 tumor-bearing nude mice after intravenous injection of the Cy5.5-PTX-SA-CMC NPs for 1, 4, 8, 12, 24, 48, and
72 h. (b) Ex vivo NIR fluorescence images of normal organs and tumors dissected from BEL-7404 tumor-bearing nude mice at 72 h post-injection of Cy5.5-PTX-SA-
CMC NPs. (c) Mean fluorescence signals of the dissected organs and tumors at 30 h post-injection. (d and e) In vivo antitumor efficiency of BEL-7402 liver tumor-
bearing nude mice after intravenous injection of physiological saline, Cremophor EL-based PTX, SA-CMC NPs, and PTX-SA-CMC NPs (14.9 wt%). (d) Relative Tumor
volume. (e) The survival rate. Tumor sizes were measured every 2–3 days. Data represents mean ± s. d. (n= 10).
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fluorescence probe was used to label the CMC backbone by coupling
NHS ester group of Cy5.5 and amine groups of CMC via stable amide
linkage. BEL-7402 human liver cancer cells were incubated with Cy5.5-
PTX-SA-CMC NPs at a fixed PTX concentration of 10 μg/mL for 1, 3, 6,
and 24 h at 37 °C and observed using the confocal laser microscopy.
Hoechst 33258 was used to identify the cell nuclei. As shown in Fig. 3d,
the Cy5.5-PTX-SA-CMC NPs (red fluorescence) were readily taken up
via BEL-7402 cells after 1 h incubation, and were evenly distributed in
the cytoplasm or around the nucleus (blue fluorescence). After 3 and 6 h
incubation, the stronger red fluorescence signal was clearly observed
inside BEL-7402 cells than that after 1 h incubation. CLSM results im-
plied that cellular uptake of PTX-SA-CMC NPs was in an endocytosis
manner. Besides, studies have shown that cellular uptake of the free
PTX was in a passive diffusion way. [42] This result indicated that PTX-
SA-CMC NPs might be internalized by BEL-7402 cells, in which the
higher amount of PTX could be delivered into the cytoplasm to induce
cell death.
3.8. In vivo passive targeting effect and biodistribution of PTX-SA-CMC NPs
(14.9 wt%)
To investigate the in vivo tumor passive targeting effect of PTX-SA-
CMC NPs (14.9 wt%), the time-dependent biodistribution was ex-
amined by noninvasive NIR imaging technique. The NIR fluorescence
probe Cy5.5-PTX-SA-CMC NPs were administrated into BEL-7402
tumor-bearing mice by intravenous injection. As shown in Fig. 4a, the in
vivo fluorescence imaging indicated that the fluorescent signals of PTX-
SA-CMC NPs were distributed in the whole body within 1 h post-in-
jection, indicating the rapid circulation of NPs in the blood stream.
Notably, the Cy5.5-PTX-SA-CMC NPs were mainly localized at the
tumor sites (Black arrows indicate the tumor site) at 4 h post-injection.
Moreover, the fluorescence signals at the tumor site continued to in-
crease up to 24 h post-injection and maintained up to 24 h. The result
suggested that the Cy5.5-PTX-SA-CMC NPs could escape the re-
ticuloendothelial systems (RES) and efficiently accumulate in the tumor
tissue. In our opinion, the result could probably be attributed to the EPR
effect-mediated passive tumor specificity of PTX-SA-CMC NPs. In ad-
dition, although the strong NIR fluorescence signal in the whole body
gradually decreased after 24 h and almost disappeared till 72 h, the
obvious NIR fluorescence signal was still accumulated at the areas of
tumor tissue. In a word, the results indicated that the Cy5.5-PTX-SA-
CMC NPs exhibited excellent passive tumor targeting efficiency.
To provide a substantial evidence of the tumor specificity of PTX-
SA-CMC NPs, major organs and tissues (heart, liver, spleen, lung,
kidney, and tumor tissues) were dissected from BEL-7402 tumor-
bearing mice at 72 h after intravenous injection of Cy5.5-PTX-SA-CMC
NPs for ex vivo fluorescence imaging (Fig. 4b). The strongest NIR
fluorescence signals was clearly observed in the tumor tissues, in-
dicating that Cy5.5-PTX-SA-CMC NPs were primarily accumulated at
the tumor sites. On the contrary, some Cy5.5-PTX-SA-CMC NPs were
localized in lung, kidney, and liver. Notably, the mean fluorescence
signal in the tumor tissues was 5.0 to 34.2-fold higher compared with
that of kidney and heart, respectively (Fig. 4c), which was a further
evidence of the passive tumor-targeting ability of PTX-SA-CMC NPs.
These results suggested that PTX-SA-CMC NPs showed excellent EPR
effect-mediated passive tumor targeting ability in BEL-7402 tumor-
bearing mice, which could help to efficiently improve the therapeutic
efficiency.
3.9. In vivo antitumor efficiency of PTX-SA-CMC NPs (14.9 wt%)
To explain the in vivo antitumor efficiency of PTX-SA-CMC NPs, the
BEL-7402 liver tumor-bearing Kunming mice were treated with
Cremophor EL-based PTX and PTX-SA-CMC NPs (14.9 wt%). These
formulations at PTX concentration of 20mg/kg (was the maximum
tolerated dose) [43] were intravenously injected into mice through the
vein tail at 0, 4, and 8 d (Fig. 4d). As controls, 200 μL of empty SA-CMC
NPs (115mg/kg) or physiological saline were also administrated into
mice. At the end of the antitumor research, the SA-CMC NPs (without
PTX) therapy produced no obvious tumor growth inhibition compared
with physiological saline group. The result indicated that SA-CMC NPs
alone had no significant inhibition influence on tumor growth. In ad-
dition, when mice were treated with Cremophor-based PTX (20mg/kg)
or PTX-SA-CMC NPs (20mg/kg), the reduction in tumor growth was
much slower. In comparison with the control group, Cremophor EL-
based PTX suppressed tumor volume by 48.8% after 35 days. Moreover,
PTX-SA-CMC NPs significantly decreased tumor volumes by 73.2%,
indicating that the antitumor effect of PTX-SA-CMC NPs was obviously
higher compared with that of Cremophor EL-based PTX. This result
suggested that the passive targeting effect of PTX-SA-CMC NPs could
enhance the accumulation of PTX within the tumor microenvironment
and inside the tumor cells, resulting in a more pronounced cytotoxicity.
Next, the in vivo survival rate of Cremophor EL-based PTX and PTX-
SA-CMC NPs (14.9 wt%) were also examined (Fig. 4e). After injection of
physiological saline and empty SA-CMC NPs, all of mice died within
40 days due to the rapid growth of tumors. In addition, the survival rate
of mice treated with Cremophor EL-based PTX and PTX-SA-CMC NPs at
the equivalent dose of PTX at 20mg/kg were 30% and 40% at 40 days,
respectively. It was deduced that the Cremophor-based PTX exhibited a
severe toxicity in tumor-bearing mice. [43] at 50 days, only 10% of
mice were still alive when treated with Cremophor EL-based PTX, while
was 40% of those were alive after treatment with PTX-SA-CMC NPs. It
should be noted that the tumor disappeared completely in three out of
10 mice treated with PTX-SA-CMC NPs at 25 days. It was considered
that the increased survival time of mice treated with PTX-SA-CMC NPs
was probably due to their better tumor growth inhibition efficacy while
decreasing the side effects. These results above suggested that PTX-SA-
CMC NPs exhibited more efficient antitumor effect, and simultaneously
showed less systemic toxicity in BEL-7402 liver tumor-bearing mice
compared with Cremophor EL-based PTX. Therefore, the SA-CMC self-
assembled NPs had a potential as a simple, safe, and effective hydro-
phobic drug carrier for cancer therapy.
4. Conclusion
Taken together, we have successfully designed and synthesized a
novel SA-CMC conjugate for the first time. It was found that the am-
phiphilic SA-CMC conjugate could be self-assembled into NPs, which
could stably load the water-insoluble PTX anticancer drug. The most
distinctive feature of PTX-SA-CMC NPs as the biocompatible and bio-
degradable system was their muti-hydrophobic inner cores, which
could remarkably accommodate the large amount of PTX. Notably,
upon the stimuli of acid, PTX-SA-CMC NPs exhibited the rapid dis-
assembly and accelerated drug release. Besides, cell experiments de-
monstrated that PTX-SA-CMC NPs had the enhanced cellular uptake
effect and cell-killing effect. Moreover, PTX-SA-CMC NPs showed ex-
cellent EPR effect-mediated passive tumor targeting ability in BEL-7402
tumor-bearing mice and achieved significant antitumor effect while
reducing systemic toxicity. Therefore, it could be expected that the self-
assembled SA-CMC NPs had potential applications as a new drug carrier
of PTX for cancer chemotherapeutic treatment.
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